Malignancies in the setting of primary immunodeficiency: Implications for hematologists/oncologists

American Journal of Hematology

Volumn 86, Issue 1, 2011, Pages 48-55

  Shapiro, Ralph S ^a  

^a Midwest Immunology Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ADENOCARCINOMA; ATAXIA TELANGIECTASIA; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; BLOOD TRANSFUSION; CANCER RISK; CARTILAGE HAIR HYPOPLASIA; CELLULAR IMMUNODEFICIENCY; COMMON VARIABLE IMMUNODEFICIENCY; DISORDERS OF DNA SYNTHESIS AND REPAIR; EPSTEIN BARR VIRUS INFECTION; GASTROINTESTINAL CARCINOMA; HELICOBACTER INFECTION; HODGKIN DISEASE; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPER IGM SYNDROME; IMMUNE DEFICIENCY; IMMUNOGLOBULIN A DEFICIENCY; LEUKEMIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NIJMEGEN BREAKAGE SYNDROME; NONHODGKIN LYMPHOMA; PHAGOCYTE DYSFUNCTION; PRIORITY JOURNAL; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; SEVERE CONGENITAL NEUTROPENIA; VIRUS CARCINOGENESIS; WISKOTT ALDRICH SYNDROME; X LINKED AGAMMAGLOBULINEMIA;

HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; NEOPLASMS;

EID: 78650365321     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21903     Document Type: Review

References (85)

1. Mueller BU, Pizzo PA. Cancer in children with primary or secondary immunodeficiencies. J Pediatr 1995; 126: 1-10.
2. Tran H, Nourse J, Hall S, et al. Immunodeficiency-associated lymphomas. Blood Rev 2008; 22: 261-281.
3. Salavoura K, Koliazlexi A, Tsangaris G, Mavrou A. Development of cancer in patients with primary immunodeficiencies. Anticancer Res 2008; 28: 1263-1270.
4. Filipovich AH, Mathur A, Kamat D, Shapiro RS. Primary immunodeficiencies: Genetic risk factors for lymphoma. Cancer Res 1992; 52: 5465-5467.
5. Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol 2007; 38: 1293-1304.
6. Gross TG, Shiramizu B. Lymphoproliferative disorders and malignancies related to immunodeficiencies. In: Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2006. pp 748-767.
7. Okano M, Gross TG. A review of Epstein-Barr Virus infection in patients with immunodeficiency disorders. Am J Med Sci 2000; 319: 392-396.
8. Carbone A, Gloghini A, Dotti G. EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist 2008; 13: 577-585.
9. Williams H, Crawford DH. Epstein-Barr virus: The impact of scientific advances on clinical practice. Blood 2006; 107: 862-869.
10. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552-565.
11. Cesarman E, Chadburn A, Liu Y-F, et al. BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood 1998; 92: 2294-2302.
12. Merlo A, Turrini R, Dolcetti R, et al. The interplay between EBV and the immune system: A rationale for adoptive cell therapy of EBV-related disorders. Haematologica Epub 2010 April 26.
13. Kersey JH, Shapiro RS, Filipovich AH. Relationship of immunodeficiency to lymphoid malignancy. Pediatr Infect Dis J 1988; 7: S10-S12.
14. Vajdic CM, Mao L, van Leeuwen MT, et al. Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency? Blood 2010; 116: 1228-1234.
15. Filipovich AH, Mathur A, Kamat D, et al. Lymphoproliferative disorders and other tumors complicating immunodeficiencies. Immunodeficiency 1994; 5: 91-112.
16. Cohen JM, Sebire NJ, Harvey J, et al. Successful treatment of lymphoproliferative disease complicating primary immunodeficiency disorders with reduced-intensity allogeneic stem-cell transplantation. Blood 2007; 110: 2209-2214.
17. Seidemann K, Tiemann M, Henze G, et al. Therapy for non-Hodgkin lymphoma in children with primary immunodeficiency: Analysis of 19 patients from the BFM trials. Med Pediatr Oncol 1999; 33: 536-544.
18. Robison LL, Stoker V, Frizzera G, et al. Hodgkin's disease in pediatric patients with naturally occurring immunodeficiency. Am J Pediatr Hematol Oncol 1987; 9: 189-192.
19. Mellemkjaer L, Hammarstrom L, Andersen V, et al. Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: A combined Danish and Swedish study. Clin Exp Immunol 2002; 130: 495-500.
20. Filipovich AH, Heinitz KJ, Robison LL, Frizzera G. The immunodeficiency Cancer Registry. A research resource. Am J Pediatr Hematol Oncol 1987; 9: 183-184.
21. Geha RS, Notarangelo LD, Casanova J-L, et al;International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. Primary immunodeficiency diseases: An update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee. J Allergy Clin Immunol 2007; 120: 776-795.
22. Cunningham-Rundles C, Lieberman P, Hellman G, Chaganti RS. Non-Hodgkin lymphoma in common variable immunodeficiency. Am J Hematol 1991; 37: 69-74.
23. Cunningham-Rundles C. Clinical and immunologic analyses of 103 patients with common variable immunodeficiency. J Clin Immunol 1989; 9: 22-33.
24. Poodt AE, Driessen GJ, de Klein A, et al. TACI mutations and disease susceptibility in patients with common variable immunodeficiency. Clin Exp Immunol 2009; 156: 35-39.
25. Yong PF, Tarzi M, Chua I, et al. Common variable immunodeficiency: An update on etiology and management. Immunol Allergy Clin North Am 2008; 28: 367-386.
26. van Zelm MC, Smet J, Adams B, et al. CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. J Clin Invest 2010; 120: 1265-1274.
27. Bonilla FA, Bernstein IL, Khan DA, et al; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005; 94:95: S1-S63.
28. Scharenberg AM, Hannibal MC, Torgerson T, et al. Common variable immune deficiency overview. GeneReviews, NIH/University of Washington, Seattle. 2006. Available at: Accessed November 2, 2009.
29. Kinlen LJ, Webster ADB, Bird AG, et al. Prospective study of cancer in patients with hypogammaglobulinemia. Lancet 1985; 1: 263-266.
30. Zullo A, Romiti A, Rinaldi V, et al. Gastric pathology in patients with common variable immunodeficiency. Gut 1999; 45: 77-81.
31. Cunningham-Rundles C, Siegal FP, Cunningham-Rundles S, Lieberman P. Incidence of cancer in 98 patients with common varied immunodeficiency. JClin Immunol 1987; 7: 294-299.
32. Kelleher P, Misbah SA. What is Good's syndrome? Immunological abnormalities in patients with thymoma. J Clin Pathol 2003; 56: 12-16.
33. Tarr PE, Sneller MC, Mechanic LJ, et al. Infections in patients with immunodeficiency with thymoma (Good syndrome). Report of 5 cases and review of the literature. Medicine (Baltimore). 2001; 80: 123-133.
34. Aghamohammadi A, Parvaneh N, Tirgari F, et al. Lymphoma of mucosa-associated lymphoid tissue in common variable immunodeficiency. Leuk Lymphoma 2006; 47: 343-346.
35. Desar IM, Keuter M, Raemaekers JM, et al. Extranodal marginal zone (MALT) lymphoma in common variable immunodeficiency. Neth J Med 2006; 64: 136-140.
36. Wheat WH, Cool CD, Morimoto Y, et al. Possible role of human herpesvirus 8 in the lymphoproliferative disorders in common variable immunodeficiency. J Exp Med 2005; 202: 479-484.
37. Chua I, Quinti I, Grimbacher B. Lymphoma in common variable immunodeficiency: Interplay between immune dysregulation, infection and genetics. Curr Opin Hematol 2008; 15: 368-374.
38. Schroeder HW, Zhu Z-B, March RE, et al. Susceptibility loucs for IgA deficiency and common variable immunodeficiency in the HLA-DR3, -B8, -A1 haplotypes. Mol Med 1998; 4: 72-86.
39. Aghamohammadi A, Mohammadi J, Parvaneh N, et al. Progression of selective IgA deficiency to common variable immunodeficiency. Int Arch Allergy Immunol 2008; 147: 87-92.
40. Imai K, Morio T, Zhu Y, et al. Clinical course of patients with WASP gene mutations. Blood 2004; 103: 456-464.
41. Bosticardo M, Marangoni F, Aiuti A, et al. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood 2009; 113: 6288-6295.
42. Thrasher AJ, Burns SO. WASP: A key immunological multitasker. Nat Rev Immunol 2010; 10: 182-192.
43. Moulding DA, Blundell MP, Spiller DG, et al. Unregulated actin polymerization by WASp causes defects of mitosis and cytokinesis in X-linked neutropenia. JEM 2007; 204: 2213-2224.
44. Pai SY, DeMartiis D, Forino C, et al. Stem cell transplantation for the Wiskott-Aldrich syndrome: A single-center experience confirms efficacy of matched unrelated donor transplantation. Bone Marrow Transplant 2006; 38: 671-679.
45. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr 1994; 125: 876-885.
46. Cotelingam JD, Witebsky FG, Hsu SM, et al. Malignant lymphoma in patients with the Wiskott-Aldrich syndrome. Cancer Invest 1985; 3: 515-522.
47. Dupre L, Andolfi G, Tangye SG, et al. SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells. Blood 2005; 105: 4383-4389.
48. Hoshino T, Kanegane H, Doki N, et al. X-linked lymphoproliferative disease in an adult. Int J Haemaol 2005; 82: 55-58.
49. Sumegi J, Huang D, Lanyi A, et al. Correlation of mutations of the SC2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood 2000; 96: 3118-3125.
50. Sumegi J, Johnson J, Filipovich A, et al. Lymphoproliferative disease, X-linked. GeneReviews. NIH/University of Washington, Seattle; 2009 update. Available at: Accessed August 25, 2010.
51. Milone MC, Tsai DE, Hodinka RL, et al. Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood 2005; 105: 994-996.
52. Hayward AR, Levy J, Facchetti F, et al. Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J Immunol 1997; 158: 977-983.
53. Erdos M, Garami M, Rakoczi E, et al. Neuroendocrine carcinoma associated with X-linked hyper-immunoglubulin M syndrome: Report of four cases and review of the literature. Clin Immunol 2008; 129: 455-461.
54. Levy J, Espanol-Boren T, Thomas C, et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr 1997; 131: 47-54.
55. Bertrand Y, Muller SM, Casanova JL, et al. Reticular dysgenesis: HLA non-identical bone marrow transplants in a series of 10 patients. Bone Marrow Transplant 2002; 29: 759-762.
56. Taskinen M, Ranki A, Pukkala E, et al. Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma. Am J Med Genet A 2008; 146A: 2370-2375.
57. Makitie O, Sulisalo T, de la Chapelle A, Kaitila I. Cartilage-hair hypoplasia. JMed Genet 1995; 32: 39-43.
58. Mäkitie O, Pukkala E, Teppo L, Kaitila I. Increased incidence of cancer in patients with cartilage-hair hypoplasia. J Pediatr 1999; 134: 315-318.
59. Taylor AMR, Metcalfe JA, Thick J, Mak Y-F. Leukemia and lymphoma in ataxia telangiectasia. Blood 1996; 87: 423-438.
60. Sandoval C, Swift M. Hodgkin disease in Ataxis-Telangiectasia patients with poor outcomes. Med Pediatr Oncol 2003; 40: 162-166.
61. Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer Inst 1986; 77: 89-92.
62. Loeb DM, Lederman HM, Winkelstein JA. Lymphoid malignancy as a presenting sign of ataxia-telangiectasia. J Pediatr Hematol Oncol 2000; 22: 464-467.
63. Gatti RA. Ataxia-telangiectasia. Dermatol Clin 1995; 13: 1-6.
64. Sandoval C, Swift M. Treatment of lymphoid malignancies in patients with Ataxia-Telangiectasia. Med Pediatr Oncol 1998; 31: 491-497.
65. Seidemann K, Henze G, Beck JD, et al. Non-Hodgkin's lymphoma in pediatric patients with chromosomal breakage syndromes (AT and NBS): Experience from the BFM trials. Ann Oncol 2000; 11: 141-145.
66. Swift M, Lukin JL. Breast cancer incidence and the effect of cigarette smoking in heterozygous carriers of mutations in the ataxia-telangiectasia gene. Cancer Epidemiol Biomarkers Prev 2008; 17: 3188-3192.
67. Gatti RA, Berkel I, Boder E, et al. Localization of an ataxia-telangiectasia gene to chromosome 11q22-23. Nature 1988; 336: 577-580.
68. Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 1991; 325: 1831-1836.
69. Su Y, Swift M. Outcomes of adjuvant radiation therapy for breast cancer in women with ataxia-telangiectasia mutations. JAMA 2001; 286: 2233-2234.
70. Lavin MF. Radiosensitivity and oxidative signaling in ataxia-telangiectasias: An update. Radiother Oncol 1998; 47: 113-123.
71. Dembowska-Baginska B, Perek D, Brozyna A, et al. Non-Hodgkin lymphoma (NHL) in children with Nijmegen Breakage Syndrome (NBS). Pediatr Blood Cancer 2009; 52: 186-190.
72. Online Mendelian Inheritance in Man (OMIM) database, Johns Hopkins University. Nijmegen Breakage Syndrome. Date of last edit: 2/12/09. Available at: Accessed October 30, 2009.
73. van der Burgt I, Chrzanowska KH, Smeets D, Weemaes C. Nijmegen breakage syndrome. J Med Genet 1996; 33: 153-156.
74. Welte K, Zeidler C. Severe congenital neutropenia. Hematol Oncol Clin North Am 2009; 23: 307-320.
75. Rosenberg PS, Alter BP, Bolyard AA, et al;for the Severe Chronic Neutropenia International Registry. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 2006; 107: 4628-4635.
76. Germeshausen M, Ballmaier M, Welte K. Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: Results of a long-term survey. Blood 2007; 109: 93-99.
77. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009; 360: 447-458.
78. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. IVIG for the prevention of infection in chronic lymphocytic leukemia. N Engl J Med 1988; 319: 902-907.
79. Griffiths H, Brennan V, Lea J, et al. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood 1989; 73: 366-368.
80. Gamm H, Huber CH, Chapel H, et al. Intravenous immune globulin in chronic lymphocytic leukemia. Clin Exp Immunol 1994; 97: 17-20.
81. Molica S, Musto P, Chiurazzi F, et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica 1996; 81: 121-126.
82. Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child 1998; 79: 48-51.
83. Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies-a prospective, multi-national study. J Clin Immunol 2006; 26: 177-185.
84. Ochs HD, Gupta S, Kiessling P, et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency disease. J Clin Immunol 26: 265-273.
85. Jeffrey Modell Foundation. 10 warning signs of primary immunodeficiency. Available at: Accessed November 6, 2009